Claire Henchcliffe

List of Publications by Year
in descending order

44 papers	2,837 citations	21 h-index (331259)	37 g-index (329751)
44 all docs	44 docs citations	44 times ranked	4720 citing authors

#	Article	IF	Citations
1	Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nature Clinical Practice Neurology, 2008, 4, 600-609.	2.7	643
2	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. JAMA Neurology, 2014, 71, 543.	4.5	312
3	Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease. New England Journal of Medicine, 2020, 382, 1926-1932.	13.9	298
4	The future of stem cell therapies for Parkinson disease. Nature Reviews Neuroscience, 2020, 21, 103-115.	4.9	178
5	Metabolomic Profiling in LRRK2-Related Parkinson's Disease. PLoS ONE, 2009, 4, e7551.	1.1	142
6	Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatric Disease and Treatment, 2009, 5, 597.	1.0	133
7	Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Movement Disorders, 2018, 33, 282-288.	2.2	122
8	Preclinical Efficacy and Safety of a Human Embryonic Stem Cell-Derived Midbrain Dopamine Progenitor Product, MSK-DA01. Cell Stem Cell, 2021, 28, 217-229.e7.	5.2	116
9	Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography. Clinical Ophthalmology, 2010, 4, 1427.	0.9	97
10	Sex and Gender Driven Modifiers of Alzheimer's: The Role for Estrogenic Control Across Age, Race, Medical, and Lifestyle Risks. Frontiers in Aging Neuroscience, 2019, 11, 315.	1.7	93
11	Data-Driven Subtyping of Parkinson's Disease Using Longitudinal Clinical Records: A Cohort Study. Scientific Reports, 2019, 9, 797.	1.6	76
12	Multinuclear Magnetic Resonance Spectroscopy for *in Vivo* Assessment of Mitochondrial Dysfunction in Parkinson's Disease. Annals of the New York Academy of Sciences, 2008, 1147, 206-220.	1.8	67
13	Rapid eye movement sleep behavior disorder and the link to alpha-synucleinopathies. Clinical Neurophysiology, 2018, 129, 1551-1564.	0.7	62
14	Biomarkers in Parkinson¼s disease. Current Opinion in Neurology, 2012, 25, 460-465.	1.8	52
15	The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. Movement Disorders, 2016, 31, 924-932.	2.2	48
16	Usefulness of Proton and Phosphorus MR Spectroscopic Imaging for Early Diagnosis of Parkinson's Disease. Journal of Neuroimaging, 2015, 25, 105-110.	1.0	43
17	Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. Expert Review of Neurotherapeutics, 2005, 5, 811-821.	1.4	41
18	Biomarkers of Parkinson's disease and Dementia with Lewy bodies. Progress in Neurobiology, 2011, 95, 601-613.	2.8	32

#	Article	IF	Citations
19	Disease Modification in ParkinsonÊ¼s Disease. Drugs and Aging, 2011, 28, 605-615.	1.3	31
20	Noninvasive PK11195â€PET Image Analysis Techniques Can Detect Abnormal Cerebral Microglial Activation in Parkinson's Disease. Journal of Neuroimaging, 2018, 28, 496-505.	1.0	29
21	Neurophysiological Biomarkers of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, 471-480.	1.5	27
22	18Fâ€FPEB PET/CT Shows mGluR5 Upregulation in Parkinson's Disease. Journal of Neuroimaging, 2019, 29, 97-103.	1.0	24
23	Late-life depression: a neuropsychiatric approach. Expert Review of Neurotherapeutics, 2006, 6, 65-72.	1.4	23
24	Sex differences in cerebral energy metabolism in Parkinson's disease: A phosphorus magnetic resonance spectroscopic imaging study. Parkinsonism and Related Disorders, 2014, 20, 545-548.	1.1	20
25	Motor phenotype classification in moderate to advanced PD in BioFIND study. Parkinsonism and Related Disorders, 2019, 65, 178-183.	1.1	20
26	First-in-human cell transplant trials in Parkinson's disease: The need for an improved informed consent process. Parkinsonism and Related Disorders, 2015, 21, 829-832.	1.1	16
27	Repairing the Brain: Cell Replacement Using Stem Cell-Based Technologies. Journal of Parkinson's Disease, 2018, 8, S131-S137.	1.5	16
28	Comprehensive subtyping of Parkinsonâ€™s disease patients with similarity fusion: a case study with BioFIND data. Npj Parkinson's Disease, 2021, 7, 83.	2.5	14
29	Molecular Imaging of Striatal Dopaminergic Neuronal Loss and the Neurovascular Unit in Parkinson Disease. Frontiers in Neuroscience, 2020, 14, 528809.	1.4	13
30	A machine learning and network framework to discover new indications for small molecules. PLoS Computational Biology, 2020, 16, e1008098.	1.5	8
31	Blood and cerebrospinal fluid markers in Parkinson&#39;s disease: current biomarker findings. Current Biomarker Findings, 0, , 1.	0.4	7
32	Can google glassâ„¢ technology improve freezing of gait in parkinsonism? A pilot study. Disability and Rehabilitation: Assistive Technology, 2023, 18, 327-332.	1.3	7
33	Restoring Function to Dopaminergic Neurons: Progress in the Development of Cell-Based Therapies for Parkinsonâ€™s Disease. CNS Drugs, 2020, 34, 559-577.	2.7	6
34	Population-based input function for TSPO quantification and kinetic modeling with [11C]-DPA-713. EJNMMI Physics, 2021, 8, 39.	1.3	6
35	Toward a Personalized Approach to Parkinson's Cell Therapy. Movement Disorders, 2020, 35, 2119-2120.	2.2	4
36	Future needs for informed consent in stem cell clinical trials in neurodegenerative diseases. Neural Regeneration Research, 2016, 11, 83.	1.6	4

#	Article	IF	Citations
37	Comorbid neuropsychiatric and autonomic features in REM sleep behavior disorder. Clinical Parkinsonism & Related Disorders, 2020, 3, 100044.	0.5	3
38	Comparison of the Parkinsonâ€™s KinetiGraph to off/on levodopa response testing: Single center experience. Clinical Neurology and Neurosurgery, 2021, 209, 106890.	0.6	3
39	Feasibility of Population-Based Input Function for Kinetic Analysis of [^{11}C]-DPA-713. , 2020, , .		1
40	Mitochondrial disorders. , 0, , 258-269.		0
41	0652 Interim Analysis from the REM Sleep Behavior Disorder Associations with Parkinsonâ€™s Disease Study (RAPiDS). Sleep, 2019, 42, A260-A260.	0.6	0
42	T165. ANTI-GLUTAMATERGIC PROPERTY OF N-ACETYLCYSTEINE DOCUMENTED IN VIVO WITH 1H MRS. Schizophrenia Bulletin, 2020, 46, S294-S294.	2.3	0
43	Tablet-based patient educational interventions in care and management of complex movement disorders. Disability and Rehabilitation: Assistive Technology, 2021, , 1-8.	1.3	0
44	Potential Therapies for Mitochondrial Dysfunction. , 2012, , 215-230.		0